Biological ActivityCOG 133 is an apolipoprotein (ApoE) peptide fragment that functions via the low-density lipoprotein receptor-related protein (LRP). Substantially reduces the symptoms of experimental autoimmune encephalomyelitis, a model of human multiple sclerosis, and suppresses inflammation, demyelination and infiltration of cells into the spinal cord. Also acts as a non-competitive antagonist at α7 nicotinic acetylcholine receptors (IC50 = 445 nM).
(Modifications: Leu-1 = N-terminal Ac, Leu-17 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Apolipoprotein E-derived peptides block α7 neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes.
Gay et al.
Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis.
Li et al.
N-MthD.-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein.
Sheng et al.
Citation for COG 133
The citations listed below are publications that use Tocris products. Selected citations for COG 133 include:
1 Citation: Showing 1 - 1
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Authors: Tavazoie Et al.
No product specific FAQs exist for this product, however you mayView all Peptide FAQs
Reviews for COG 133
There are currently no reviews for this product. Be the first to review COG 133 and earn rewards!
Have you used COG 133?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image